Total debt has climbed 179% from $140.8M in Q4 2024 to $392.2M in Q3 2026 while cash has fallen over 80% to $48.4M, pushing the current ratio down from 1.86 to 1.11 and raising the D/E ratio from 0.12 to 0.46.
Chemed Corporation (CHE) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 365.73M | 302.62M | 394.75M | 500.84M | 272.61M | 230.29M | 329.4M | 190.67M | 159.84M | 176.05M | 169.9M | 150.81M | 174.56M | 224.66M | 197.67M | 150.75M | 196.8M | 198.26M | 136.26M | 139.41M | 162.11M | 204.25M | 197.62M | 102.08M | 96.23M | 100.05M | 106.47M | 111.8M | 124.6M | 177.5M | 192.4M |
| Cash & Short-Term Investments | 48.43M | 74.52M | 178.35M | 263.96M | 74.13M | 32.9M | 162.68M | 6.16M | 4.83M | 11.12M | 15.31M | 14.73M | 14.13M | 84.42M | 69.53M | 38.08M | 49.92M | 112.42M | 3.63M | 4.99M | 29.27M | 57.13M | 71.45M | 50.59M | 37.73M | 9.01M | 10.28M | 17.3M | 41.4M | 71M | 11.9M |
| Cash Only | 48.43M | 74.52M | 178.35M | 263.96M | 74.13M | 32.9M | 162.68M | 6.16M | 4.83M | 11.12M | 15.31M | 14.73M | 14.13M | 84.42M | 69.53M | 38.08M | 49.92M | 112.42M | 3.63M | 4.99M | 29.27M | 57.13M | 71.45M | 50.59M | 37.73M | 9.01M | 10.28M | 17.3M | 41.4M | 71M | 11.9M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 254.86M | 182.57M | 171.16M | 181.51M | 139.41M | 137.22M | 126.85M | 143.83M | 119.5M | 113.65M | 132.02M | 106.26M | 124.61M | 91.77M | 93.33M | 77.92M | 113M | 53.46M | 98.08M | 103.11M | 93.09M | 91.09M | 64.66M | 14.35M | 14.64M | 15.13M | 54.57M | 55.9M | 45.3M | 42.1M | 31.6M |
| Days Sales Outstanding | 28.86 | 26.34 | 25.7 | 29.26 | 23.83 | 23.41 | 22.26 | 27.08 | 24.47 | 24.89 | 30.56 | 25.13 | 31.23 | 23.7 | 23.82 | 20.98 | 32.21 | 16.39 | 31.16 | 34.21 | 33.36 | 36.3 | 32.12 | 20.09 | 21.07 | 16.34 | 56.06 | 44.98 | 43.36 | 44.97 | 38.29 |
| Inventory | 7.75M | 7.54M | 8.19M | 12M | 10.27M | 10.11M | 7.09M | 7.46M | 5.71M | 5.33M | 5.75M | 6.31M | 6.17M | 6.7M | 7.06M | 8.67M | 7.73M | 7.54M | 7.57M | 6.6M | 6.58M | 6.5M | 7.02M | 8.26M | 9.49M | 10.42M | 10.5M | 9.8M | 9.8M | 8.7M | 52.4M |
| Days Inventory Outstanding | 1.51 | 1.55 | 1.9 | 2.99 | 2.74 | 2.69 | 1.88 | 2.06 | 1.7 | 1.69 | 1.88 | 2.12 | 2.18 | 2.43 | 2.49 | 3.26 | 3.11 | 3.3 | 3.41 | 3.14 | 3.29 | 3.68 | 5.06 | 20.52 | 24.58 | 18.5 | 18.34 | 13.26 | 15.52 | 15.41 | 107.21 |
| Other Current Assets | 16.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.2M | 23.95M | 13.66M | 12.54M | 15.1M | 13.7M | 15.39M | 14.21M | 23.21M | 31.92M | 44.65M | 24.01M | 22.22M | 57.98M | 31.12M | 28.8M | 28.1M | 55.7M | 50.5M |
| Total Non-Current Assets | 1.35B | 1.34B | 1.27B | 1.17B | 1.17B | 1.11B | 1.11B | 1.08B | 815.69M | 743.98M | 710.16M | 701.52M | 685.37M | 669.04M | 661.96M | 645.15M | 633.36M | 621.21M | 624.66M | 632.91M | 631.17M | 630.84M | 627.95M | 226.98M | 242.7M | 296.46M | 314.9M | 309.5M | 305.1M | 271.3M | 367M |
| Property, Plant & Equipment | 360.99M | 336.81M | 328.16M | 330.23M | 335.38M | 318.73M | 311.27M | 287.42M | 162.03M | 143.03M | 121.3M | 117.37M | 105.34M | 92.95M | 91.93M | 82.95M | 79.29M | 75.36M | 76.96M | 74.51M | 70.14M | 65.45M | 55.8M | 41M | 48.36M | 67.59M | 75.18M | 71.7M | 61.7M | 53.1M | 83.3M |
| Fixed Asset Turnover | 10.93x | 7.51x | 7.41x | 6.86x | 6.37x | 6.71x | 6.68x | 6.74x | 11.00x | 11.65x | 13.00x | 13.15x | 13.83x | 15.20x | 15.56x | 16.35x | 16.15x | 15.79x | 14.93x | 14.76x | 14.52x | 14.00x | 13.17x | 6.36x | 5.25x | 5.00x | 4.73x | 6.33x | 6.18x | 6.44x | 3.62x |
| Goodwill | 754.76M | 667M | 666.74M | 585.02M | 581.29M | 578.59M | 578.59M | 577.37M | 510.57M | 476.89M | 472.37M | 472.32M | 466.72M | 466.87M | 465.83M | 460.63M | 458.34M | 450.04M | 448.72M | 438.69M | 435.05M | 0 | 0 | 0 | 0 | 161.07M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 78.79M | 82.76M | 92.21M | 90.26M | 99.73M | 108.1M | 118.08M | 126.37M | 68.25M | 54.87M | 55.06M | 55.11M | 56.03M | 56.56M | 57.18M | 58.26M | 56.41M | 57.92M | 61.3M | 65.18M | 69.22M | 509.11M | 509.66M | 105.93M | 113.73M | 4.04M | 180.72M | 175.9M | 168.9M | 156.6M | 204.2M |
| Long-Term Investments | 577.12M | 140.35M | 0 | 0 | 0 | 98.88M | 88.81M | 77.45M | 65.62M | 62.07M | 54.39M | 49.48M | 49.15M | 42.47M | 36.09M | 31.63M | 28.3M | 24.16M | 22.63M | 29.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 13.33M | 8.65M | 186.72M | 161.74M | 153M | 8.14M | 8.76M | 9.05M | 9.21M | 7.13M | 7.04M | 7.23M | 8.14M | 10.2M | 10.92M | 11.68M | 11.02M | 13.73M | 14.07M | 25.11M | 56.77M | 63.9M | 62.49M | 89.62M | 82.04M | 109.82M | 59.01M | 61.9M | 74.5M | 61.6M | 218.7M |
| Total Assets | 1.72B | 1.64B | 1.67B | 1.67B | 1.44B | 1.34B | 1.43B | 1.27B | 975.53M | 920.03M | 880.06M | 852.33M | 859.93M | 893.7M | 859.63M | 795.9M | 830.16M | 819.47M | 760.92M | 772.31M | 793.29M | 835.09M | 825.57M | 329.07M | 338.93M | 396.51M | 421.38M | 421.3M | 429.7M | 448.8M | 559.4M |
| Asset Turnover | 1.64x | 1.54x | 1.46x | 1.36x | 1.48x | 1.59x | 1.45x | 1.53x | 1.83x | 1.81x | 1.79x | 1.81x | 1.69x | 1.58x | 1.66x | 1.70x | 1.54x | 1.45x | 1.51x | 1.42x | 1.28x | 1.10x | 0.89x | 0.79x | 0.75x | 0.85x | 0.84x | 1.08x | 0.89x | 0.76x | 0.54x |
| Asset Growth % | -14.97% | -1.71% | 0.03% | 15.68% | 7.39% | -6.42% | 13.13% | 30.01% | 6.03% | 4.54% | 3.25% | -0.88% | -3.78% | 3.96% | 8.01% | -4.13% | 1.3% | 7.69% | -1.47% | -2.64% | -5.01% | 1.15% | 150.88% | -2.91% | -14.52% | -5.9% | 0.02% | -1.95% | -4.26% | -19.77% | 5.17% |
| Total Current Liabilities | 330.93M | 287.13M | 285.69M | 312.05M | 297.2M | 302.4M | 299.11M | 262.22M | 191.67M | 193.52M | 171.83M | 171.34M | 175.55M | 363.99M | 156.82M | 145.4M | 149.34M | 136.08M | 154.05M | 152.83M | 166.06M | 168.9M | 169.18M | 59.09M | 69.87M | 85.11M | 106.94M | 98.4M | 91.1M | 94.4M | 124.5M |
| Accounts Payable | 65.3M | 53.46M | 44.15M | 64.03M | 41.88M | 73.02M | 54.23M | 51.1M | 50.15M | 48.37M | 39.59M | 43.7M | 46.85M | 41.76M | 48.47M | 48.23M | 55.83M | 52.07M | 52.81M | 46.17M | 49.74M | 43.44M | 37.78M | 6.08M | 5.69M | 9.13M | 11.1M | 11.2M | 10.3M | 8.8M | 9M |
| Days Payables Outstanding | 11.78 | 11.01 | 10.22 | 15.95 | 11.16 | 19.46 | 14.36 | 14.12 | 14.91 | 15.35 | 12.95 | 14.66 | 16.53 | 15.11 | 17.12 | 18.14 | 22.49 | 22.77 | 23.78 | 21.97 | 24.87 | 24.6 | 27.21 | 15.12 | 14.72 | 16.2 | 19.39 | 15.15 | 16.31 | 15.59 | 18.41 |
| Short-Term Debt | 0 | 51.89M | 0 | 15.7M | 5M | 0 | 0 | 0 | 0 | 10M | 8.75M | 7.5M | 6.25M | 183.56M | 0 | 0 | 0 | 0 | 10.17M | 10.16M | 209K | 1.04M | 12.19M | 193K | 409K | 353K | 14.38M | 11.7M | 4.4M | 5.3M | 17.5M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.36M | 17.32M | 22.19M | 24.97M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 58.34M | 120.95M | 134.75M | 121.87M | 145.84M | 134.63M | 133.88M | 114.44M | 93.57M | 86.4M | 73.73M | 74.94M | 75.07M | 73.48M | 61.6M | 59.94M | 16.14M | 14.13M | 12.18M | 13.93M | 41.66M | 53.35M | 75.84M | 32.47M | 23.88M | 58.02M | 56.49M | 75.5M | 76.4M | 80.3M | 63.9M |
| Current Ratio | 1.11x | 1.05x | 1.38x | 1.61x | 0.92x | 0.76x | 1.10x | 0.73x | 0.83x | 0.91x | 0.99x | 0.88x | 0.99x | 0.62x | 1.26x | 1.04x | 1.32x | 1.46x | 0.88x | 0.91x | 0.98x | 1.21x | 1.17x | 1.73x | 1.38x | 1.18x | 1.00x | 1.14x | 1.37x | 1.88x | 1.55x |
| Quick Ratio | 1.08x | 1.03x | 1.35x | 1.57x | 0.88x | 0.73x | 1.08x | 0.70x | 0.80x | 0.88x | 0.96x | 0.84x | 0.96x | 0.60x | 1.22x | 0.98x | 1.27x | 1.40x | 0.84x | 0.87x | 0.94x | 1.17x | 1.13x | 1.59x | 1.24x | 1.05x | 0.90x | 1.04x | 1.26x | 1.79x | 1.12x |
| Cash Conversion Cycle | 18.59 | 16.88 | 17.37 | 16.3 | 15.41 | 6.64 | 9.78 | 15.02 | 11.25 | 11.24 | 19.49 | 12.59 | 16.88 | 11.02 | 9.19 | 6.1 | 12.83 | -3.08 | 10.78 | 15.38 | 11.78 | 15.38 | 9.96 | 25.49 | 30.93 | 18.64 | 55.01 | 43.09 | 42.57 | 44.79 | 127.09 |
| Total Non-Current Liabilities | 526.08M | 373.48M | 263.89M | 248.17M | 346.09M | 417.05M | 234.6M | 279.49M | 192.53M | 186.15M | 184.13M | 167.74M | 233.02M | 80.83M | 249.51M | 236.82M | 218.77M | 206.22M | 208.72M | 255.13M | 205.86M | 285.72M | 324.29M | 67.07M | 74.98M | 104.89M | 86.03M | 110.9M | 115.2M | 126.3M | 201.1M |
| Long-Term Debt | 236M | 0 | 0 | 0 | 92.5M | 185M | 0 | 90M | 89.2M | 91.2M | 100M | 83.75M | 141.25M | 0 | 174.89M | 166.78M | 159.21M | 152.13M | 199.66M | 214.67M | 150.33M | 234.06M | 279.51M | 25.93M | 25.6M | 61.04M | 58.39M | 78.6M | 80.4M | 83.7M | 158.2M |
| Capital Lease Obligations | 435.82M | 102.87M | 98.54M | 100.78M | 110.51M | 100.63M | 99.21M | 86.66M | 0 | -61.8M | -54.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 169.62M | 121.14M | 25.95M | 30.32M | 38.61M | 23.18M | 20.66M | 18.5M | 21.6M | 16.64M | 14.29M | 21.04M | 29.95M | 27.3M | 27.66M | 29.46M | 25.09M | 25.92M | 7.6M | 5.8M | 26.3M | 22.3M | 16.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.7M |
| Other Non-Current Liabilities | 156.24M | 13.34M | 139.4M | 117.07M | 104.47M | 108.24M | 114.73M | 84.33M | 81.73M | 78.31M | 69.84M | 62.95M | 61.83M | 53.52M | 46.96M | 40.57M | 34.48M | 28.17M | 28.03M | 34.66M | 29.23M | 25.65M | 27.97M | 41.14M | 49.37M | 43.85M | 27.64M | 32.3M | 34.8M | 42.6M | 40M |
| Total Liabilities | 857.02M | 660.61M | 549.58M | 560.22M | 643.3M | 719.45M | 533.71M | 541.71M | 384.19M | 379.67M | 355.96M | 339.07M | 408.58M | 444.81M | 406.33M | 382.22M | 368.11M | 342.31M | 389.33M | 407.96M | 371.93M | 450.91M | 493.47M | 136.38M | 135.65M | 173.99M | 192.97M | 209.3M | 206.3M | 220.7M | 330.7M |
| Total Debt | 392.19M | 154.76M | 140.84M | 155.11M | 247.01M | 323.54M | 135.41M | 215.94M | 89.2M | 101.2M | 108.75M | 91.25M | 147.5M | 183.56M | 174.89M | 166.78M | 159.21M | 152.13M | 209.82M | 224.83M | 150.54M | 235.1M | 291.69M | 26.38M | 26.01M | 61.39M | 72.77M | 90.3M | 84.8M | 89M | 175.8M |
| Net Debt | 343.77M | 80.24M | -37.51M | -108.85M | 172.88M | 290.65M | -27.27M | 209.78M | 84.37M | 90.08M | 93.44M | 76.52M | 133.37M | 99.15M | 105.36M | 128.7M | 109.29M | 39.71M | 206.2M | 219.84M | 121.27M | 177.97M | 220.25M | -24.21M | -11.72M | 52.38M | 62.49M | 73M | 43.4M | 18M | 163.9M |
| Debt / Equity | 0.46x | 0.16x | 0.13x | 0.14x | 0.31x | 0.52x | 0.15x | 0.30x | 0.15x | 0.19x | 0.21x | 0.18x | 0.33x | 0.41x | 0.39x | 0.40x | 0.34x | 0.32x | 0.56x | 0.62x | 0.36x | 0.61x | 0.88x | 0.14x | 0.13x | 0.28x | 0.32x | 0.43x | 0.38x | 0.39x | 0.77x |
| Debt / EBITDA | 0.89x | 0.38x | 0.33x | 0.39x | 0.61x | 0.80x | 0.30x | 0.71x | 0.32x | 0.68x | 0.51x | 0.42x | 0.74x | 1.13x | 0.94x | 0.91x | 0.92x | 0.99x | 1.31x | 1.52x | 1.17x | 2.30x | 3.73x | 12.56x | 2.88x | 1.53x | 1.28x | 1.93x | 2.27x | 2.56x | 4.08x |
| Net Debt / EBITDA | 0.78x | 0.20x | -0.09x | -0.27x | 0.43x | 0.72x | -0.06x | 0.69x | 0.30x | 0.61x | 0.44x | 0.35x | 0.67x | 0.61x | 0.56x | 0.70x | 0.63x | 0.26x | 1.29x | 1.48x | 0.94x | 1.74x | 2.81x | -11.52x | -1.30x | 1.31x | 1.10x | 1.56x | 1.16x | 0.52x | 3.80x |
| Interest Coverage | 76.96x | 204.30x | 225.42x | 113.73x | 72.92x | 188.53x | 169.15x | 58.69x | 49.02x | 28.37x | 48.66x | 50.42x | 20.81x | 9.24x | 10.90x | 11.12x | 12.19x | 11.40x | 21.31x | 10.06x | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 861.42M | 979.4M | 1.12B | 1.11B | 798.72M | 623.27M | 901.2M | 726.61M | 591.33M | 540.35M | 524.1M | 513.25M | 451.36M | 448.89M | 453.29M | 413.68M | 462.05M | 477.16M | 371.59M | 364.35M | 421.36M | 384.18M | 332.09M | 192.69M | 203.28M | 222.52M | 228.41M | 212M | 223.4M | 228.1M | 228.7M |
| Equity Growth % | -91.41% | -12.47% | 1% | 38.71% | 28.15% | -30.84% | 24.03% | 22.88% | 9.43% | 3.1% | 2.11% | 13.71% | 0.55% | -0.97% | 9.57% | -10.47% | -3.17% | 28.41% | 1.99% | -13.53% | 9.68% | 15.68% | 72.34% | -5.21% | -8.65% | -2.58% | 7.74% | -5.1% | -2.06% | -0.26% | -8.41% |
| Book Value per Share | 65.58 | 68.02 | 73.69 | 72.89 | 52.90 | 39.11 | 54.96 | 43.96 | 35.19 | 32.28 | 31.22 | 29.46 | 25.30 | 24.15 | 23.44 | 19.75 | 20.06 | 20.98 | 15.90 | 14.53 | 15.80 | 14.61 | 13.48 | 9.68 | 10.28 | 11.45 | 11.50 | 10.08 | 11.06 | 11.39 | 11.54 |
| Total Shareholders' Equity | 861.42M | 979.4M | 1.12B | 1.11B | 798.72M | 623.27M | 901.2M | 726.61M | 591.33M | 540.35M | 524.1M | 513.25M | 451.36M | 448.89M | 453.29M | 413.68M | 462.05M | 477.16M | 371.59M | 364.35M | 421.36M | 384.18M | 332.09M | 192.69M | 203.28M | 222.52M | 228.41M | 212M | 223.4M | 228.1M | 217.9M |
| Common Stock | 37.76M | 37.59M | 37.42M | 37.18M | 36.8M | 36.51M | 36.26M | 35.81M | 35.31M | 34.73M | 34.27M | 33.98M | 33.34M | 32.24M | 31.59M | 30.94M | 30.38M | 29.89M | 29.52M | 29.26M | 28.85M | 28.37M | 13.49M | 13.45M | 13.45M | 13.44M | 13.32M | 13.7M | 0 | 0 | 0 |
| Retained Earnings | 3.14B | 2.96B | 2.72B | 2.45B | 2.2B | 1.97B | 1.72B | 1.43B | 1.23B | 1.04B | 958.15M | 865.85M | 771.18M | 686.11M | 623.03M | 546.76M | 473.32M | 403.37M | 343.81M | 278.34M | 215.52M | 171.19M | 141.54M | 119.75M | 132.79M | 139.16M | 153.91M | 144.3M | 147M | 148.7M | 139.3M |
| Treasury Stock | -4.01B | -3.61B | -3.13B | -2.72B | -2.59B | -2.43B | -1.82B | -1.6B | -1.45B | -1.23B | -1.11B | -991.98M | -894.28M | -752.63M | -640.73M | -564.09M | -408.62M | -293.94M | -285.98M | -213.04M | -78.06M | -52.13M | -33.87M | -109.43M | -111.58M | -110.42M | -105.25M | -99.4M | 0 | 0 | 0 |
| Accumulated OCI | 0 | 2.35M | 0 | 0 | 0 | 0 | 2.34M | 2.31M | 2.34M | 2.2M | 2.51M | 2.4M | 2.28M | 2.15M | 2.04M | 1.99M | 0 | 0 | 0 | 2.48M | 2.42M | 1.83M | -1.76M | -1.58M | 319K | -1.44M | -10.83M | -11.1M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.8M |
Quick answers to the most common questions about buying CHE stock.
As of 2025, Chemed Corporation (CHE) had total assets of $1.64B including $302.6M in current assets.
Chemed Corporation (CHE) carries total debt of $154.8M, offset by $74.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Chemed Corporation (CHE) has total shareholders' equity (book value) of $979.4M ($68.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Chemed Corporation (CHE) reported a current ratio of 1.05x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Debt-funded buybacks eroding cushion
Metrics are mathematically derived from official filings.
Net Cash Position Inverts to Rising Leverage
Chemed's balance sheet has undergone a material transformation, with total debt rising 179% from $140.8M in Q4 2024 to $392.2M in Q3 2026 while cash fell from $178.3M to $48.4M, inverting the historically net-cash posture into a net-debt position. According to quarterly SEC filings.
This structural shift coincides with the cash flow finding that buybacks of approximately $1.18B over ten quarters have exceeded cumulative operating cash flow of $950.7M, suggesting management has drawn on debt to sustain its repurchase program. Total equity declined from $1.2B to $861.4M despite retained earnings growing by $500M, confirming that buyback-driven treasury stock accumulation is eroding the equity cushion. The D/E ratio's ascent from 0.12 to 0.46 remains moderate in absolute terms, but the trajectory warrants close monitoring if cash generation continues to weaken as the free cash flow margin compresses.
Leverage Ramp Tracks Buyback Funding Gap
Based on Chemed's reported balance sheets, total debt has more than doubled since Q1 2026 — rising from $236.9M to $392.2M in just two quarters — with the D/E ratio climbing from 0.28 to 0.46, representing the steepest quarterly borrowing pace in the ten-quarter window.
The acceleration in borrowing from a relatively stable $140–150M range through Q3 2025 to $392.2M appears consistent with the capital deployment pattern identified in the cash flow analysis, where buybacks have outpaced operating cash generation by roughly $230M. While a D/E of 0.46 remains well below the Ensign Group (ENSG) peer at 1.86 and even Addus (ADUS) at 0.19 is closer in absolute terms, the velocity of leverage expansion — not the absolute level — is the concern. Investors should assess whether this borrowing is transitional to support a temporary buyback acceleration or reflects a structural shift in capital allocation philosophy, as the latter would materially change the risk profile.
Cash Runway Narrows as Buffer Depletes
As reported in Chemed's quarterly filings, the current ratio has deteriorated from 1.86 in Q2 2025 to 1.11 in Q3 2026, while cash reserves have fallen from $249.9M to $48.4M — a decline of over 80% — leaving the thinnest liquidity cushion in the ten-quarter observation period.
A current ratio of 1.11 remains above the 1.0 threshold but has compressed materially from historical norms of 1.4–1.9, suggesting limited room for further deterioration without approaching working capital stress. The simultaneous decline in cash and increase in debt indicates that liquidity has been deliberately deployed rather than eroded by operating losses, but the buffer against reimbursement timing delays or working capital swings — which the cash flow analysis showed can swing $110M quarter-to-quarter — is now meaningfully thinner. Given VITAS's exposure to government payment timing and audit-driven clawbacks, this compressed buffer warrants close monitoring in upcoming quarters.
Buybacks Erode Equity Despite Earnings Accretion
According to Chemed's financial statements, total equity has contracted from $1.2B to $861.4M over ten quarters even as retained earnings expanded from $2.6B to $3.1B, implying that approximately $540M in share repurchases and treasury stock activity has consumed the equity base faster than earnings replenish it.
This dynamic is the natural counterpart to the buyback program that has deployed $1.18B over ten quarters, exceeding $950.7M in cumulative operating cash flow as previously noted in the cash flow analysis. The $500M increase in retained earnings signals genuine profitability, but the equity erosion confirms that capital return has been funded partly through balance sheet reserves and new borrowing rather than purely from organic cash generation. The practical effect is a smaller equity denominator amplifying ROE optics, which should be discounted when assessing genuine returns on invested capital.
Goodwill Creep and PPE Halving Under Scrutiny
Based on Chemed's reported figures, goodwill has expanded from $662.1M to $754.8M over the period — a $93M increase — while net PPE has collapsed from $334.5M to $144.0M, a 57% decline that raises questions about asset disposition, lease reclassification, or portfolio restructuring not yet reflected in headline results.
Goodwill now represents approximately 88% of total equity, meaning the reported book value is almost entirely comprised of acquisition-related intangible assets whose impairment risk is non-trivial given the regulatory headwinds facing VITAS. The simultaneous $190M decline in PPE is stark — it could indicate asset sales, a shift toward leasing, or a reclassification, but the balance sheet data alone does not confirm the driver and warrants investigation into the Q3 2025 to Q4 2025 transition where PPE dropped sharply. Given that goodwill has historically constituted over 45% of total assets, any impairment tied to hospice reimbursement deterioration would materially erode an equity cushion that already appears compressed by the aggressive buyback program.